Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 261

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary Hypertension

Sebkhi, A., Strange, Julian W., Phillips, Steven C., Wharton, John, Wilkins, Martin R. · 2003 · Circulation

Abstract

Background— Phosphodiesterase type 5 (PDE5) is a novel therapeutic target for the treatment of pulmonary hypertension. This study examined the distribution of PDE5 in normal and hypoxic lung and the effect of chronic PDE5 inhibition with sildenafil, initiated before and during exposure to hypoxia, on pulmonary artery pressure (PAP) and structure. Methods and Results— Sprague-Dawley rats were exposed to hypoxia (10% O 2 ) for up to 42 days. PAP, measured continuously by telemetry, increased gradually by 20 to 40 mm Hg, reaching a plateau between 10 and 14 days, and declined to normal levels on return to normoxia. PDE5 immunoreactivity was localized to smooth muscle cells in the medial layer of pulmonary arteries and veins in the normal lung and in distal muscularized arteries (<25 μm diameter) after hypoxia-induced pulmonary hypertension. Sildenafil (25 or 75 mg · kg −1 · d −1 ) given before hypoxia produced marked dose-dependent inhibition in the rise of PAP (60% to 90% reduction; P <0.0001) and vascular muscularization (28.4±5.0% reduction; P <0.001). When begun after 14 days of hypoxia, sildenafil significantly reduced PAP (30% reduction; P <0.0001) and partially reversed pulmonary artery muscularization (39.9±4.9% reduction; P <0.001). Conclusions— PDE5 is found throughout the muscularized pulmonary vascular tree, including in newly muscularized distal pulmonary arteries exposed to hypoxia. PDE5 inhibition attenuates the rise in PAP and vascular remodeling when given before chronic exposure to hypoxia and when administered as a treatment during ongoing hypoxia-induced pulmonary hypertension.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000074226.20466.b1

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 261

Metadata

Authors
Sebkhi, A., Strange, J. W., Phillips, S. C., Wharton, J., & Wilkins, M. R.
Venue
Circulation
Published
2003-07
Volume
107
Issue
25
Pages
3230-3235
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1989792368
Cited by
261
References
12
FWCI
18.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary Hypertension. https://app.cochat.ai/papers/10.1161/01.cir.0000074226.20466.b1
The paper
Sebkhi, A., Strange, J. W., Phillips, S. C., Wharton, J., & Wilkins, M. R. (2003). Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary Hypertension. Circulation. https://doi.org/10.1161/01.cir.0000074226.20466.b1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.